论文部分内容阅读
自从30多年前报导首例抗体缺陷综合症以来,用丙种球蛋白补充治疗问题已不是过去的“用与不用”,而是“用多大剂量”,“多久时间”和最近提出的“怎样用”(什么途径)的问题了。 Bernatowska等人提供的一些资料,有助于解决这些问题。在交叉试验中,Berna-towska的研究组对静注免疫球蛋白(IVIG)的两种剂量(高剂量:500mg/kg体重/月和低剂量:150mg/kg体重/月),进行了对比。由于被研究的12名儿童中的8名,在二年前曾接受过血浆输注补充(20mg/kg体重/月),因此也有可能与该治疗法作回顾性比较研究。 在血浆治疗期间,其血浆补充治疗取得的经验是很显著的,8名中有5名儿童出现肝功试验(LFTs)异常。但仅用IvIG的患儿,未发现肝功试验异常,甚至使用多种不
Since the first antibody deficiency syndrome was reported more than 30 years ago, the issue of using gammaglobuline to supplement treatment is not “yes or no” in the past, but “how many doses”, “how long”, and the recently proposed “how to use” (What path) the problem. Some information provided by Bernatowska et al. Can help solve these problems. In a crossover trial, Berna-towska’s group compared two doses of intravenous immunoglobulin (IVIG) (high dose: 500 mg / kg body weight / month and low dose: 150 mg / kg body weight / month). Since 8 out of 12 children studied had received plasma infusion supplements (20 mg / kg body weight / month) two years ago, it is also possible to conduct a retrospective comparison with this treatment. The experience gained with plasma-supplemented therapies was significant during plasma therapy, with 5 out of 8 children presenting with abnormal liver function tests (LFTs). However, only children with IvIG, liver function tests found no abnormalities, or even use a variety of not